John Gribben, MD, DSc, FRCPath, FMed Sci from Barts Cancer Institute, London, UK compares the use of generic drugs to biosimilars at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Generic drugs have several benefits including reduced costs to patients and healthcare providers alike. The introduction of biosimilars is also an attempt to replace expensive drugs in chemo-immunotherapy. However, biosimilars are not identical to the original product, they are similar, and as a result, they are extensively vetted and tested to ensure that there are no differences in efficacy and safety, and therefore patient outcomes.This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates